Hodgkin lymphoma, HIV, and Epstein–Barr virus in Malawi: Longitudinal results from the Kamuzu Central Hospital Lymphoma study

Westmoreland, Katherine D.; Stanley, Christopher C.; Montgomery, Nathan D.; Kaimila, Bongani; Kasonkanji, Edwards; El-Mallawany, Nader Kim; Wasswa, Peter; Mtete, Idah; Butia, Mercy; Itimu, Salama; Chasela, Mary; Mtunda, Mary; Chikasema, Maria; Makwakwa, Victor; Kampani, Coxcilly; Dhungel, Bal M.; Sanders, Marcia K.; Krysiak, Robert; Tomoka, Tamiwe; Liomba, N. George; Dittmer, Dirk P.; Fedoriw, Yuri; Gopal, Satish

- Add this to...
- Twitter
- Facebook
- Google Bookmarks
- LinkedIn

Hodgkin lymphoma, HIV, and Epstein–Barr virus in Malawi: Longitudinal results from the Kamuzu Central Hospital Lymphoma study

Published Date:

Oct 26 2016

Source:

Pediatr Blood Cancer. 64(5).

Language:

English

[PDF-590.29 KB]

Details:

Personal Authors:

Westmoreland, Katherine D. ; Stanley, Christopher C. ; Montgomery, Nathan D. ; Kaimila, Bongani ; Kasonkanji, Edwards ; ... More ▼

Keywords:

[+]

Pubmed ID:

27781380

Pubmed Central ID:

PMC5529120

Description:

Background

Contemporary descriptions of classical Hodgkin lymphoma (cHL) are lacking from sub-Saharan Africa where human immunodeficiency virus (HIV) and Epstein–Barr virus (EBV) are prevalent.

Methods

We describe a prospective cHL cohort in Malawi enrolled from 2013 to 2015. Patients received standardized treatment and evaluation, including HIV status and EBV testing of tumors and plasma.

Results

Among 31 patients with confirmed cHL, the median age was 19 years (range, 2–51 years) and 22 (71%) were male. Sixteen patients (52%) had stage III/IV, 25 (81%) B symptoms, and 16 (52%) performance status impairment. Twenty-three patients (74%) had symptoms >6 months, and 11 of 29 (38%) had received empiric antituberculosis treatment. Anemia was common with median hemoglobin 8.2 g/dL (range, 3.1–17.1 g/dL), which improved during treatment. No children and 5 of 15 adults (33%)were HIV+. All HIV+ patients were on antiretroviral therapy for a median 15 months (range, 2–137 months), with median CD4 count 138 cells/μL (range, 23–329 cells/μL) and four (80%) having undetectable HIV. EBV was present in 18 of 24 (75%) tumor specimens, including 14 of 20 (70%) HIV− and 4 of 4 (100%) HIV+. Baseline plasma EBV DNA was detected in 25 of 28 (89%) patients, with median viral load 4.7 (range, 2.0–6.7) log10copies/mL, and subsequently declined in most patients. At 12 months, overall survival was 75% (95% confidence interval [CI], 55%–88%) and progression-free survival 65% (95% CI, 42%–81%). Baseline plasma EBV DNA and persistent viremia during treatment were associated with poorer outcomes.

Conclusion

cHL in Malawi is characterized by delayed diagnosis and advanced disease. Most cases were EBV associated and one-third of adults were HIV+. Despite resource limitations, 12-month outcomes were good.

Document Type:

Journal Article

Collection(s):

CDC Public Access

Funding:

R21 CA180097/CA/NCI NIH HHS/United States
K01 TW009488/TW/FIC NIH HHS/United States
U54 CA190152/CA/NCI NIH HHS/United States
P20 CA210285/CA/NCI NIH HHS/United States
P30 AI050410/AI/NIAID NIH HHS/United States
R21 CA180815/CA/NCI NIH HHS/United States
U2G PS001965/PS/NCHHSTP CDC HHS/United States

Place as Subject:

Africa South of the Sahara ; Malawi ;

Supporting Files:

	nihms880309.nxml	text/xml
	nihms880309f1.gif	image/gif
	nihms880309f1.jpg	image/jpeg
	nihms880309f2.gif	image/gif
	nihms880309f2.jpg	image/jpeg
	nihms880309f3.gif	image/gif
	nihms880309f3.jpg	image/jpeg

No Related Documents.

You May Also Like:

Plasma Epstein-Barr virus DNA for pediatric Burkitt lymphoma diagnosis, prognosis, and response assessment in Malawi

Personal Author:

Westmoreland, Katherine D.; Montgomery, Nathan D.; Stanley, Christopher C.; El-Mallawany, Nader Kim; Wasswa, Peter; van der Gronde, Toon; Mtete, Idah; Butia, Mercy; Itimu, Salama; Chasela, Mary; Mtunda, Mary; Kampani, Coxcilly; Liomba, N. George; Tomoka, Tamiwe; Dhungel, Bal M.; Sanders, Marcia K.; Krysiak, Robert; Kazembe, Peter; Dittmer, Dirk P.; Fedoriw, Yuri; Gopal, Satish;

Published:

Mar 24 2017

Source:

Int J Cancer. 140(11):2509-2516.

Description:

Point-of-care tools are needed in sub-Saharan Africa (SSA) to improve pediatric Burkitt lymphoma (BL) diagnosis and treatment. We evaluated plasma Epstein-Barr virus (pEBV) DNA as a pediatric BL biomarker in Malawi. Prospectively enrolled children wi...

File Type:

[PDF - 492.94 KB]
Outcomes for paediatric Burkitt lymphoma treated with anthracycline-based therapy in Malawi

Personal Author:

Stanley, Christopher C.; Westmoreland, Kate D.; Heimlich, Brett J.; El-Mallawany, Nader K.; Wasswa, Peter; Mtete, Idah; Butia, Mercy; Itimu, Salama; Chasela, Mary; Mtunda, Mary; Chikasema, Mary; Makwakwa, Victor; Kaimila, Bongani; Kasonkanji, Edwards; Chimzimu, Fred; Kampani, Coxcilly; Dhungel, Bal M.; Krysiak, Robert; Montgomery, Nathan D.; Fedoriw, Yuri; Rosenberg, Nora E.; Liomba, George N.; Gopal, Satish;

Published:

Feb 23 2016

Source:

Br J Haematol. 173(5):705-712.

Description:

Burkitt lymphoma (BL) is the most common paediatric cancer in sub-Saharan Africa (SSA). Anthracyline-based treatment is standard in resource-rich settings, but has not been described in SSA. Children ≤18 years of age with newly diagnosed BL were p...

File Type:

[PDF - 455.13 KB]
Mature outcomes and prognostic indices in diffuse large B-cell lymphoma in Malawi: a prospective cohort

Personal Author:

Painschab, Matthew S.; Kasonkanji, Edwards; Zuze, Takondwa; Kaimila, Bongani; Tomoka, Tamiwe; Nyasosela, Richard; Nyirenda, Ruth; Dhungel, Bal M.; Mulenga, Maurice; Chikasema, Maria; Tewete, Blessings; Mtangwanika, Asekanadziwa; Chiyoyola, Sarah; Mhango, Wilberforce; Chimzimu, Fred; Kampani, Coxcilly; Krysiak, Robert; Shea, Thomas C.; Montgomery, Nathan D.; Fedoriw, Yuri; Gopal, Satish;

Published:

Nov 18 2018

Source:

Br J Haematol. 184(3):364-372

Description:

Outcomes for diffuse large B-cell lymphoma (DLBCL) in sub-Saharan Africa (SSA) are poorly described. We report mature data from one of the first prospective SSA cohorts. Patients aged ≥18 years with DLBCL were enrolled in Malawi 2013-2017. Partici...

Public Access
Available on:

February 01, 2020
‘Discovering’ primary effusion lymphoma in Malawi

Personal Author:

Dhungel, Bal Mukunda; Montgomery, Nathan D.; Painschab, Matthew S.; Mulenga, Maurice; Tomoka, Tamiwe; Kaimila, Bongani; Zuze, Takondwa; Kasonkanji, Edwards; Kampani, Coxcilly; Chimzimu, Fred; Randall, Cara; Krysiak, Robert; Seguin, Ryan; Fedoriw, Yuri; Gopal, Satish;

Published:

Sep 24 2018

Source:

AIDS. 32(15):2264-2266.

Public Access
Available on:

September 24, 2019
Serological Assessment of 18 Pathogens and Risk for AIDS-associated Non-Hodgkin Lymphoma

Personal Author:

Halec, Gordana; Waterboer, Tim; Brenner, Nicole; Butt, Julia; Hardy, David W.; D’Souza, Gypsyamber; Wolinsky, Steven; Macatangay, Bernard J.; Pawlita, Michael; Detels, Roger; Martínez-Maza, Otoniel; Hussain, Shehnaz K.;

Published:

Mar 01 2019

Source:

J Acquir Immune Defic Syndr. 80(3):e53-e63

Description:

Background: : HIV infection is associated with increased susceptibility to common pathogens which may trigger chronic antigenic stimulation and hyperactivation of B-cells, events known to precede the development of AIDS-associated non-Hodgkin lymphom...

Public Access
Available on:

March 01, 2020